{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:14:11Z","timestamp":1793996051019,"version":"4.8.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP) are chronic inflammatory skin conditions. Accumulating evidence shows that GPP and PPP have different characteristics to plaque psoriasis and are distinct clinical entities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the epidemiology, comorbidities, mortality and healthcare use for patients in England with GPP and PPP versus those with plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We carried out a cohort study involving analyses of longitudinal electronic health record data in the Clinical Practice Research Datalink Aurum database and linked hospital and mortality data between 2008 and 2019. The primary study outcome was the incidence and prevalence rates of GPP, PPP and plaque psoriasis in England. Secondary outcomes included survival rates and healthcare resource use (HCRU) by disease type.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 373 patients with GPP, 1828 with PPP and 224 223 with plaque psoriasis. Mean (SD) age was 55.9 (18.6) years for patients with GPP, 51.5 (16.4) years for those with PPP and 48.5 (19.1) years for those with plaque psoriasis; 62.5% and 65.9% of patients with GPP and PPP, respectively, were women, vs. 49.4% of those with plaque psoriasis. About half of patients were overweight or obese at baseline (GPP 48.6%, PPP 56.0%, plaque psoriasis 45.9%). The incidence rates for GPP, PPP and plaque psoriasis were 0.25 [95% confidence interval (CI) 0.21\u20130.28], 2.01 (95% CI 1.92\u20132.11) and 103.2 (95% CI 102.5\u2013103.9) per 100 000 person-years, respectively. From 2008 to 2019, the prevalence rates per 100 000 persons ranged from 1.61 to 3.0 for GPP, from 1.1 to 18.7 for PPP and from 1771.0 to 1903.8 for plaque psoriasis. Survival rates were lower for patients with GPP, particularly those who were &amp;gt; 55\u2005years of age and those with a history of one or more comorbidities in each cohort. HCRU was lower in the cohort with plaque psoriasis and highest in the cohort with GPP, particularly among those who had more than one GPP flare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results provide further evidence that, in England, GPP is a distinct disease with different epidemiology, lower survival and higher HCRU than plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljae217","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T16:46:42Z","timestamp":1716310002000},"page":"529-538","source":"Crossref","is-referenced-by-count":21,"title":["Prevalence, incidence, mortality and healthcare resource use for generalized pustular psoriasis, palmoplantar pustulosis and plaque psoriasis in England: a population-based cohort study"],"prefix":"10.1093","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5729-778X","authenticated-orcid":false,"given":"Monika","family":"Frysz","sequence":"first","affiliation":[{"name":"Boehringer Ingelheim Ltd , Bracknell , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smit","family":"Patel","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Ltd , Bracknell , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u00a0Oy Yee","family":"Li","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Ltd , Bracknell , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E M","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Department of Dermatology, King\u2019s College Hospital, King\u2019s College London , London , UK"},{"name":"NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-6481","authenticated-orcid":false,"given":"Richard B","family":"Warren","sequence":"additional","affiliation":[{"name":"NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK"},{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren M","family":"Ashcroft","sequence":"additional","affiliation":[{"name":"NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK"},{"name":"Centre for Pharmacoepidemiology and Drug Safety, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"2024091723511017000_ljae217-B1","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/jdv.14386","article-title":"European consensus statement on phenotypes of pustular psoriasis","volume":"31","author":"Navarini","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024091723511017000_ljae217-B2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaci.2018.06.038","article-title":"Clinical and genetic differences between pustular psoriasis subtypes","volume":"143","author":"Twelves","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2024091723511017000_ljae217-B3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/1744666X.2019.1708193","article-title":"The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review","volume":"16","author":"Kharawala","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"2024091723511017000_ljae217-B4","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1600-0560.2010.01612.x","article-title":"The histopathological spectrum of acute generalized exanthematous pustulosis (AGEP) and its differentiation from generalized pustular psoriasis","volume":"37","author":"Kardaun","year":"2010","journal-title":"J Cutan Pathol"},{"key":"2024091723511017000_ljae217-B5","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1111\/1346-8138.16022","article-title":"Patient characteristics and burden of disease in Japanese patients with generalized pustular psoriasis: results from the Medical Data Vision claims database","volume":"48","author":"Morita","year":"2021","journal-title":"J Dermatol"},{"key":"2024091723511017000_ljae217-B6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s13555-021-00493-0","article-title":"Unmet medical needs in the treatment and management of generalized pustular psoriasis flares: evidence from a survey of Corrona Registry dermatologists","volume":"11","author":"Strober","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2024091723511017000_ljae217-B7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40257-021-00654-z","article-title":"Clinical course and characteristics of generalized pustular psoriasis","volume":"23","author":"Choon","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"2024091723511017000_ljae217-B8","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2133.1968.tb11947.x","article-title":"Generalized pustular psoriasis: a clinical and epidemiological study of 104 cases","volume":"80","author":"Baker","year":"1968","journal-title":"Br J Dermatol"},{"key":"2024091723511017000_ljae217-B9","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/humu.22203","article-title":"Mutation analysis of the IL36RN gene in 14 Japanese patients with generalized pustular psoriasis","volume":"34","author":"Farooq","year":"2013","journal-title":"Hum Mutat"},{"key":"2024091723511017000_ljae217-B10","doi-asserted-by":"crossref","first-page":"e23068","DOI":"10.1097\/MD.0000000000023068","article-title":"Association between mutation of interleukin 36 receptor antagonist and generalized pustular psoriasis: a PRISMA-compliant systematic review and meta-analysis","volume":"99","author":"Liu","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"2024091723511017000_ljae217-B11","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1013068","article-title":"Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis","volume":"365","author":"Marrakchi","year":"2011","journal-title":"N Engl J Med"},{"key":"2024091723511017000_ljae217-B12","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ajhg.2014.04.005","article-title":"AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking","volume":"94","author":"Setta-Kaffetzi","year":"2014","journal-title":"Am J Hum Genet"},{"key":"2024091723511017000_ljae217-B13","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1038\/jid.2013.230","article-title":"The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist","volume":"133","author":"Sugiura","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2024091723511017000_ljae217-B14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"2024091723511017000_ljae217-B15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.12703\/r\/10-62","article-title":"Recent advances in palmoplantar pustulosis","volume":"10","author":"Brunasso","year":"2021","journal-title":"Fac Rev"},{"key":"2024091723511017000_ljae217-B16","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/1744666X.2022.2116003","article-title":"Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion","volume":"18","author":"Bachelez","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"2024091723511017000_ljae217-B17","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s40265-022-01801-4","article-title":"Spesolimab: first approval","volume":"82","author":"Blair","year":"2022","journal-title":"Drugs"},{"key":"2024091723511017000_ljae217-B18","author":"European Medicines Agency"},{"key":"2024091723511017000_ljae217-B19","author":"Medicines & Healthcare products Regulatory Agency"},{"key":"2024091723511017000_ljae217-B20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/bjd\/ljad083","article-title":"Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial","volume":"189","author":"Warren","year":"2023","journal-title":"Br J Dermatol"},{"key":"2024091723511017000_ljae217-B21","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/03007995.2021.1894108","article-title":"Economic burden of generalized pustular psoriasis and palmoplantar pustulosis in the United States","volume":"37","author":"Hanna","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"2024091723511017000_ljae217-B22","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1001\/jamadermatol.2022.3142","article-title":"Understanding flares in patients with generalized pustular psoriasis documented in US electronic health records","volume":"158","author":"Zema","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2024091723511017000_ljae217-B23","author":"Medicines & Healthcare products Regulatory Agency"},{"key":"2024091723511017000_ljae217-B24","author":"NHS England"},{"key":"2024091723511017000_ljae217-B25","doi-asserted-by":"crossref","first-page":"AB20","DOI":"10.1016\/j.jaad.2021.06.107","article-title":"Characterization of flares in patients with generalized pustular psoriasis \u2013 a population-based study from the French National Health Data System database (SNDS)","volume":"85","author":"Bachelez","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2024091723511017000_ljae217-B26","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/jdv.18720","article-title":"Prevalence, comorbidities and mortality of generalized pustular psoriasis: a literature review","volume":"37","author":"Prinz","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024091723511017000_ljae217-B27","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/bjd.20966","article-title":"Prevalence and incidence of generalized pustular psoriasis in Sweden: a population-based register study","volume":"186","author":"L\u00f6fvendahl","year":"2022","journal-title":"Br J Dermatol"},{"key":"2024091723511017000_ljae217-B28","first-page":"89","article-title":"Economic burden of generalized pustular psoriasis in Sweden: a population-based register study","volume":"12","author":"L\u00f6fvendahl","year":"2022","journal-title":"Psoriasis (Auckl)"},{"key":"2024091723511017000_ljae217-B29","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2022.09.049","article-title":"Comorbidities in patients with generalized pustular psoriasis- a nationwide population-based register study","volume":"88","author":"L\u00f6fvendahl","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2024091723511017000_ljae217-B30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/jvc2.285","article-title":"Prevalence of multiple long-term conditions with psoriasis in England: a cohort study using the Clinical Practice Research Datalink","volume":"3","author":"Payne","year":"2024","journal-title":"JEADV Clin Pract"},{"key":"2024091723511017000_ljae217-B31","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/ije\/dyz034","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum","volume":"48","author":"Wolf","year":"2019","journal-title":"Int J Epidemiol"},{"key":"2024091723511017000_ljae217-B32","first-page":"602","article-title":"Validity of The Health Improvement Network (THIN) for the study of psoriasis","volume":"164","author":"Seminara","year":"2011","journal-title":"Br J Dermatol"},{"key":"2024091723511017000_ljae217-B33","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/ije\/dyx015","article-title":"Data resource profile: Hospital Episode Statistics Admitted Patient Care (HES APC)","volume":"46","author":"Herbert","year":"2017","journal-title":"Int J Epidemiol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae217\/58575944\/ljae217.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/4\/529\/59122352\/ljae217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/4\/529\/59122352\/ljae217.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T19:51:27Z","timestamp":1726602687000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/191\/4\/529\/7679321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,5,22]]},"published-print":{"date-parts":[[2024,9,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae217","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,5,22]]}}}